US2017304415A1PendingUtilityA1
Anti-Cancer Combination Treatment and Kit-of-Parts
Est. expiryJun 15, 2025(expired)· nominal 20-yr term from priority
Inventors:Bjørn Kristiansen
A61K 2039/585A61K 45/06A61P 35/00A61K 31/70A61K 39/0002
53
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
In one aspect the present invention relates to pharmaceutical kits of parts suitable for treating neoplastic diseases such as cancer comprising an anti-cancer medicament, a Basidiomycete bioactive agent in solid or liquid form, and, optionally instructions for a dosing regime.
Claims
exact text as granted — not AI-modified1 . A pharmaceutical kit of parts comprising
a) an anti-cancer medicament, b) a Basidiomycete bioactive agent in solid or liquid form, and, optionally c) instructions for a dosing regime.
2 . The kit according to claim 1 , wherein the anti-cancer medicament is selected from the group consisting of:
Aldesleukin/Proleukin (Chiron Corp) Alemtuzumab/Campath (Millennium and ILEX Partners, LP) alitretinoin/Panretin (Ligand Pharmaceuticals) allopurinol/Zyloprim (GlaxoSmithKline) altretamine/Hexalen (US Bioscience) amifostine/Ethyol (US Bioscience) anastrozole/Arimidex (AstraZeneca) arsenic trioxide/Trisenox (Cell Therapeutic) Asparaginase/Elspar (Merck & Co, Inc) BCG Live/TICE BCG (Organon Teknika Corp) bexarotene capsules/Targretin (Ligand Pharmaceuticals) bleomycin/Blenoxane (Bristol-Myers Squibb) busulfan/Busulfex (GlaxoSmithKline) calusterone/Methosarb (Pharmacia & Upjohn Company) capecitabine/Xeloda (Roche) carboplatin/Paraplatin (Bristol-Myers Squibb) carmustine/BCNU, BiCNU (Bristol-Myers Squibb) carmustine with Polifeprosan 20 Implant/Gliadel Wafer (Guilford Pharmaceuticals Inc.) celecoxib/Celebrex (Searle) chlorambucil/Leukeran (GlaxoSmithKline) cisplatin/Platinol (Bristol-Myers Squibb) cladribine/Leustatin, 2-CdA (R. W. Johnson Pharmaceutical Research Institute) cyclophosphamide Cytoxan/Neosar (Bristol-Myers Squibb) cytarabine/Cytosar-U (Pharmacia & Upjohn Company) dacarbazine/DTIC-Dome (Bayer) dactinomycin/actinomycin D Cosmegen (Merck) Darbepoetin alfa/Aranesp (Amgen, Inc) daunorubicin/daunomycin/Daunorubicin (Bedford Labs) daunorubicin/daunomycin/Cerubidine (Wyeth Ayerst) Denileukin/diftitox/Ontak (Seragen, Inc) dexrazoxane/Zinecard (Pharmacia & Upjohn Company) docetaxel/Taxotere (Aventis Pharmaceutical) doxorubicin Adriamycin/Rubex (Pharmacia & Upjohn Company) Dromostanolone propionate/Masterone Injection (Syntex) Elliott's B Solution (Orphan Medical, Inc) epirubicin/Ellence (Pharmacia & Upjohn Company) etoposide phosphate (Bristol-Myers Squibb) etoposide/VP-16/Vepesid (Bristol-Myers Squibb) exemestane/Aromasin (Pharmacia & Upjohn Company) Filgrastim/Neupogen (Amgen, Inc) floxuridine/FUDR (Roche) fludarabine/Fludara (Berlex Laboratories Inc.) fluorouracil/5-FU/Adrucil (ICN Puerto Rico) fulvestrant/Faslodex (IPR) gemcitabine/Gemzar (Eli Lilly) gemtuzumab/ozogamicin/Mylotarg (Wyeth Ayerst) goserelin acetate/Zoladex Implant (AstraZeneca Pharmaceuticals) hydroxyurea/Hydrea (Bristol-Myers Squibb) Ibritumomab Tiuxetan/Zevalin (IDEC Pharmaceuticals Corp) idarubicin/Idamycin (Adria Laboratories) ifosfamide/IFEX (Bristol-Myers Squibb) imatinib mesylate/Gleevec (Novartis) Interferon alfa-2a/Roferon-A (Hoffmann-La Roche Inc) Interferon alfa-2b/Intron A (Schering Corp) irinotecan/Camptosar (Pharmacia & Upjohn Company) letrozole/Femara (Novartis) leucovorin Wellcovorin/Leucovorin (Immunex Corporation) levamisole/Ergamisol (Janssen Research Foundation) lomustine/CCNU/CeeBU (Bristol-Myers Squibb) meclorethamine/nitrogen mustard/Mustargen (Merck) megestrol acetate/Megace (Bristol-Myers Squibb) melphalan/L-PAM/Alkeran (GlaxoSmithKline) mercaptopurine/6-MP Purinethol (GlaxoSmithKline) mesna/Mesnex (Asta Medica) methotrexate (Lederle Laboratories) methoxsalen/Uvadex (Therakos) mitomycin C/Mutamycin (Bristol-Myers Squibb) mitomycin C/Mitozytrex (Supergen) mitotane/Lysodren (Bristol-Myers Squibb) mitoxantrone/Novantrone (Lederle Laboratories) nandrolone phenpropionate/Durabolin-50 (Organon) Nofetumomab/Verluma (Boehringer Ingelheim Pharma KG (formerly Dr. Karl Thomae GmbH)) Oprelvekin/Neumega (Genetics Institute) oxaliplatin/Eloxatin (Sanofi Synthelabo) paclitaxel/Taxol (Bristol-Myers Squibb) pamidronate/Aredia (Novartis) pegademase/Adagen (Pegademase Bovine) (Enzon) Pegaspargase/Oncaspar (Enzon, Inc) Pegfilgrastim/Neulasta (Amgen, Inc) pentostatin/Nipent (Parke-Davis Pharmaceutical Co.) pipobroman/Vercyte (Abbott Labs) plicamycin/mithramycin/Mithracin (Pfizer Labs) porfimer sodium/Photofrin (QLT Phototherapeutics Inc.) procarbazine/Matulane (Sigma Tau Pharms) quinacrine/Atabrine (Abbott Labs) Rasburicase/Elitek (Sanofi-Synthelabo, Inc) Rituximab/Rituxan (Genentech, Inc) Sargramostim/Prokine (Immunex Corp) streptozocin/Zanosar (Pharmacia & Upjohn Company) talc/Sclerosol (Bryan) tamoxifen/Nolvadex (AstraZeneca Pharmaceuticals) temozolomide/Temodar (Schering) teniposide/VM-26/Vumon (Bristol-Myers Squibb) testolactone/Teslac (Bristol-Myers Squibb) thioguanine/6-TG/Thioguanine (GlaxoSmithKline) thiotepa/Thioplex (Lederle Laboratories) topotecan/Hycamtin (GlaxoSmithKline) topotecan/Hycamtin (GlaxoSmithKline) toremifene/Fareston (Orion Corp) Tositumomab/Bexxar (Corixa Corporation) Trastuzumab/Herceptin (Genentech, Inc) tretinoin/ATRA/Vesanoid (Roche) Uracil Mustard (Roberts Labs) valrubicin/Valstar (Medeva) vinblastine/Velban (Eli Lilly) vincristine/Oncovin (Eli Lilly) vinorelbine/Navelbine (GlaxoSmithKline), and zoledronate/Zometa (Novartis)
3 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is Aldesleukin/Proleukin (Chiron Corp)
4 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is Alemtuzumab/Campath (Millennium and ILEX Partners, LP), such as for the treatment or prophylaxis of B-cell chronic lymphocytic leukaemia (B-CLL)
5 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is alitretinoin/Panretin (Ligand Pharmaceuticals), such as for the treatment or prophylaxis of cutaneous lesions in sarcoma patients, such as in patients suffering from AIDS-related Kaposi's sarcoma.
6 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is allopurinol/Zyloprim (GlaxoSmithKline), such as for the treatment of patients with leukaemia and/or lymphoma and/or one or more solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels.
7 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is altretamine/Hexalen (US Bioscience), such as for treatment or prophylaxis of ovarian cancer.
8 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is amifostine/Ethyol (US Bioscience), such as for treatment or prophylaxis of post-radiation xerostomia for e.g. head and neck cancer and/or ovarian cancer (preferably advanced) and/or non-small cell lung cancer.
9 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is anastrozole/Arimidex (AstraZeneca), such as for the treatment of breast cancer, for example hormone receptor positive early breast cancer, advanced breast cancer, locally advanced or metastatic breast cancer.
10 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is arsenic trioxide/Trisenox (Cell Therapeutic).
11 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is Asparaginase/Elspar (Merck & Co, Inc), such as for the treatment of pediatric patients.
12 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is BCG Live/TICE BCG (Organon Teknika Corp).
13 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is bexarotene capsules/Targretin (Ligand Pharmaceuticals), such as for treatment of cutaneous manifestations of cutaneous T-cell lymphoma, preferably via oral administration.
14 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is bleomycin/Blenoxane (Bristol-Myers Squibb), such as for treatment of malignant pleural effusion (MPE) and prevention of recurrent pleural effusions.
15 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is busulfan/Busulfex (GlaxoSmithKline), such as prior to hematopoietic progenitor cell transplantation for chronic myelogenous leukemia, preferably via oral administration.
16 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is calusterone/Methosarb (Pharmacia & Upjohn Company).
17 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is capecitabine/Xeloda (Roche), such as for treatment of breast cancer, preferably metastatic breast cancer, or colorectal carcinoma, preferably metastatic colorectal carcinoma.
18 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is Carboplatin/Paraplatin (Bristol-Myers Squibb), such as for treatment of ovarian carcinoma.
19 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is carmustine/BCNU, BiCNU (Bristol-Myers Squibb)
20 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is carmustine with Polifeprosan 20 Implant/Gliadel Wafer (Guilford Pharmaceuticals Inc.), such as to prolong survival in patients with recurrent glioblastoma multiforme who qualify for surgery.
21 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is celecoxib/Celebrex (Searle), such as for treatment of familial adenomatous polyposis.
22 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is chlorambucil/Leukeran (GlaxoSmithKline), such as for treatment of chronic lymphocytic leukaemia.
23 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is cisplatin/Platinol (Bristol-Myers Squibb), such as for treatment of ovarian tumour preferably metastatic ovarian tumour, testicular tumour, preferably testicular tumour, transitional cell bladder cancer.
24 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is cladribine/Leustatin, 2-CdA (R. W. Johnson Pharmaceutical Research Institute), such as for treatment of active hairy cell leukaemia.
25 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is cyclophosphamide Cytoxan/Neosar (Bristol-Myers Squibb)
26 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is cytarabine/Cytosar-U (Pharmacia & Upjohn Company)
27 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is dacarbazine/DTIC-Dome (Bayer).
28 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is dactinomycin/actinomycin D Cosmegen (Merck)
29 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is Darbepoetin alfa/Aranesp (Amgen, Inc), such as for treatment of anemia associated with chemotherapeutic regimes.
30 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is daunorubicin/daunomycin/Daunorubicin (Bedford Labs), such as in liposomal form, for example for the treatment of HIV-related Kaposi's sarcoma.
31 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is daunorubicin/daunomycin/Cerubidine (Wyeth Ayerst), such as for treatment of leukaemia.
32 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is Denileukin/diftitox/Ontak (Seragen, Inc), such as for treatment of T-cell lymphoma, preferably of individuals whose malignant cells express the CDC25 component of the IL-2 receptor.
33 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is dexrazoxane/Zinecard (Pharmacia & Upjohn Company), such as to aid in reducing the severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer.
34 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is docetaxel/Taxotere (Aventis Pharmaceutical), such as for treatment of breast cancer, preferably locally advanced or metastatic breast cancer, or non-small cell lung cancer, preferably locally advanced or metastatic non-small cell lung cancer.
35 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is doxorubicin/Adriamycin Rubex (Pharmacia & Upjohn Company), such as for treatment of AIDS-related Kaposi's sarcoma or metastatic carcinoma of the ovary.
36 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is Dromostanolone propionate/Masterone injection (SYNTEX).
37 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is Elliott's B Solution (Orphan Medical, Inc), such as for treatment or prophylaxis of miningeal leukaemia or lymphocytic lymphoma.
38 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is Epirubicin/Ellence (Pharmacia & Upjohn Company), such as for treatment or prophylaxis of breast cancer.
39 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is etoposide phosphate (Bristol-Myers Squibb), such as for treatment or prophylaxis of refractory testicular tumours, or small cell lung cancer.
40 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is etoposide/VP-16/Vepesid (Bristol-Myers Squibb), such as for treatment or prophylaxis of refractory testicular tumours, small cell lung cancer.
41 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is exemestane/Aromasin (Pharmacia & Upjohn Company), such as for treatment or prophylaxis of breast cancer, preferably for treatment of advanced breast cancer.
42 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is Filgrastim/Neupogen (Amgen, Inc), such as for treatment of non-myeloid malignancies undergoing myeloablative chemotherapy followed by marrow transplantation.
43 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is floxuridine/FUDR (Roche)
44 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is fludarabine/Fludara (Berlex Laboratories Inc.), such as for treatment or prophylaxis of B-cell lymphocytic leukaemia.
45 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is fluorouracil/5-FU/Adrucil (ICN Puerto Rico), such as to prolong survival.
46 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is fulvestrant/Faslodex (IPR), such as for treatment or prophylaxis of breast cancer, preferably in post-menopausal women.
47 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is gemcitabine/Gemzar (Eli Lilly), such as for treatment or prophylaxis of adenocarcinoma of the pancreas or non-small cell lung cancer, preferably locally advanced or metastatic adenocarcinoma of the pancreas or non-small cell lung cancer.
48 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is gemtuzumab/ozogamicin/Mylotarg (Wyeth Ayerst), such as for treatment or prophylaxis of CD33 positive acute myeloid leukaemia in patients who are preferably 60 years of age or older.
49 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is goserelin acetate/Zoladex Implant (AstraZeneca Pharmaceuticals), such as for treatment or prophylaxis of breast cancer, preferably advanced stage breast cancer.
50 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is hydroxyurea/Hydrea (Bristol-Myers Squibb).
51 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is Ibritumomab Tiuxetan/Zevalin (IDEC Pharmaceuticals Corp), such as for treatment or prophylaxis of non-Hodgkin's lymphoma, for example patients with Rituximab refractory follicular non-Hodgkin's lymphoma.
52 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is idarubicin/Idamycin (Adria Laboratories), such as for treatment or prophylaxis of acute myeloid leukaemia, for example in adults.
53 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is ifosfamide/IFEX (Bristol-Myers Squibb), such as for treatment of germ cell testicular cancer.
54 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is imatinib mesylate/Gleevec (Novartis), such as for treatment of chronic myelogeneous leukaemia or gastrointestinal stromal tumours.
55 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is Interferon alfa-2a/Roferon-A (Hoffmann-La Roche Inc), such as for treatment or prophylaxis of malignant melanoma, Non-Hodgkin's Lymphoma, condylomata acuminate, hairy cell leukaemia or AIDS-related Kaposi's sarcoma.
56 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is Interferon alfa-2b/Intron A (Schering Corp).
57 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is irinotecan/Camptosar (Pharmacia & Upjohn Company), such as for treatment or prophylaxis of carcinoma of the colon or rectum, preferably metastatic carcinoma of the colon or rectum.
58 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is letrozole/Femara (Novartis), carcinoma of the colon or rectum, such as for treatment or prophylaxis of breast cancer, preferably in post-menopausal women.
59 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is Leucovorin/Wellcovorin (Immunex Corporation), such as for treatment or prophylaxis of colorectal cancer, preferably advanced colorectal cancer.
60 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is levamisole/Ergamisol (Janssen Research Foundation), such as for treatment or prophylaxis of colon cancer, preferably after surgical resection.
61 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is lomustine/CCNU/CeeBU (Bristol-Myers Squibb).
62 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is meclorethamine/nitrogen mustard/Mustargen (Merck)
63 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is megestrol acetate/Megace (Bristol-Myers Squibb)
64 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is melphalan/L-PAM/Alkeran (GlaxoSmithKline), such as for treatment or prophylaxis of multiple myeloma.
65 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is mercaptopurine/6-MP Purinethol (GlaxoSmithKline)
66 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is mesna/Mesnex (Asta Medica) such as for treatment or prophylaxis of ifosfamide-indeuced hemorrhagic cystitis.
67 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is methotrexate (Lederle Laboratories), such as for treatment or prophylaxis of osteosarcoma.
68 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is methoxsalen/Uvadex (Therakos), such as for treatment or prophylaxis of skin manifestations of cutaneous T-cell lymphoma (CTCL).
69 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is mitomycin C/Mutamycin (Bristol-Myers Squibb).
70 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is mitomycin C/Mitozytrex (Supergen), such as for treatment or prophylaxis of disseminated adenocarcinoma of the stomach or pancreas.
71 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is mitotane/Lysodren (Bristol-Myers Squibb)
72 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is mitoxantrone/Novantrone (Lederle Laboratories), such as for treatment or prophylaxis of prostrate cancer or acute nonlymphocytic leukaemia (ANLL) in adults.
73 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is nandrolone phenpropionate/Durabolin-50 (Organon).
74 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is Nofetumomab/Verluma (Boehringer Ingelheim Pharma KG (formerly Dr. Karl Tomae GmbH).
75 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is doxorubicin/Adriamycin PFS.
76 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is Oprelvekin/Neumega (Genetics Institute), preferably administered after myelosuppressive chemotherapy in patients with nonmyeloid malignancies
77 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is oxaliplatin/Eloxatin (Sanofi Synthelabo), such as for treatment or prophylaxis of carcinoma of the colon, preferably metastatic carcinoma of the colon.
78 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is paclitaxel/Taxol/Paxene (Bristol-Myers Squibb), such as for treatment or prophylaxis of advanced AIDS-related Kaposi's sarcoma, breast cancer, metastatic breast cancer, carcinoma of the ovary, AIDS-related Kaposi's sarcoma, metastatic carcinoma of the ovary, non-small cell lung cancer or node-positive breast cancer.
79 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is pamidronate/Aredia (Novartis), such as for treatment or prophylaxis of osteolytic bone metastases of breast cancer.
80 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is pegademase/Adagen (Pegademase Bovine) (Enzon).
81 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is Pegaspargase/Oncaspar (Enzon, Inc).
82 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is Pegfilgrastim/Neulasta (Amgen, Inc), such as for treatment or prophylaxis of non-myeloid malignancies.
83 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is pentostatin/Nipent (Parke-Davis Pharmaceutical Co.), such as for treatment or prophylaxis of hairy cell leukaemia, for example alpha interferon refractory hairy cell leukaemia.
84 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is pipobroman/Vercyte (Abbott Labs)
85 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is plicamycin/mithramycin/Mithracin (Pfizer Labs)
86 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is porfimer sodium/Photofrin (QLT Phototherapeutics Inc.), such as for the treatment or prophylaxis of partially obstructing or completely obstructing esophogeal cancer.
87 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is procarbazine/Matulane (Sigma Tau Pharms).
88 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is quinacrine/Atabrine (Abbott Labs)
89 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is Rasburicase/Elitek (Sanofi-Synthelabo, Inc), such as for the treatment or prophylaxis of patients suffering from leukaemia, lymphoma or solid tumor malignancies.
90 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is Rituximab/Rituxan (Genentech, Inc)
91 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is Sargramostim/Prokine (Immunex Corp)
92 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is streptozocin/Zanosar (Pharmacia & Upjohn Company).
93 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is talc/Sclerosol (Bryan), such as for the treatment or prophylaxis of malignant pleural effusion in symptomatic patients.
94 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is tamoxifen/Nolvadex (AstraZeneca Pharmaceuticals), such as for the treatment or prophylaxis of breast cancer, for example following mastectomy and axillary dissection in postmenopausal women, or for metastatic breast cancer, for example in men.
95 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is temozolomide/Temodar (Schering), such as for the treatment or prophylaxis of refractory anaplastic astrocytma.
96 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is teniposide/VM-26/Vumon (Bristol-Myers Squibb), such as for the treatment or prophylaxis of refractory childhood acute lymphoblastic leukaemia.
97 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is testolactone/Teslac (Bristol-Myers Squibb)
98 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is thioguanine/6-TG/Thioguanine (GlaxoSmithKline)
99 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is thiotepa/Thioplex (Lederle Laboratories)
100 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is topotecan/Hycamtin (GlaxoSmithKline), such as for the treatment or prophylaxis of metastatic carcinoma of the ovary, or small cell lung cancer.
101 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is toremifene/Fareston (Orion Corp), such as for the treatment or prophylaxis of advanced breast cancer in postmenopausal women.
102 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is Tositumomab/Bexxar (Corixa Corporation), such as for the treatment or prophylaxis of non-Hodgkin's lymphoma.
103 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is Trastuzumab/Herceptin (Genentech, Inc), such as for the treatment or prophylaxis of metastatic breast cancer.
104 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is tretinoin/ATRA/Vesanoid (Roche), such as for the treatment or prophylaxis of acute promyeocytic leukaemia.
105 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is Uracil Mustard (Roberts Labs)
106 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is valrubicin/Valstar (Medeva), such as for the treatment or prophylaxis of BCG-refractory carcinoma in situ (CIS) of the urinary bladder.
107 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is vinblastine/Velban (Eli Lilly)
108 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is vincristine/Oncovin (Eli Lilly)
109 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is vinorelbine/Navelbine (GlaxoSmithKline), such as for the treatment or prophylaxis of non-small cell lung cancer, such as unresectable, advanced non-small cell lung cancer.
110 . The kit according to any of claims 1 and 2 , wherein the anti-cancer drug is zoledronate/Zometa (Novartis), such as for the treatment or prophylaxis of multiple myeloma or patients with documented bone metastases from solid tumours.
111 . The kit according to any of claims 1 to 110 , wherein the Basidiomycete bioactive agent is selected from the group consisting of:
agents comprising or consisting of an oligosaccharide,
agents comprising or consisting of a polysaccharide,
agents comprising or consisting of an optionally glycosylated peptide,
agents comprising or consisting of an optionally glycosylated polypeptide,
agents comprising or consisting of an oligonucleotide,
agents comprising or consisting of a polynucleotide,
agents comprising or consisting of a lipid,
agents comprising or consisting of a fatty acid,
agents comprising or consisting of a fatty acid ester and
agents comprising or consisting of secondary metabolites.
112 . The kit according to any of claims 1 to 111 , wherein the bioactive agent is selected from the group consisting of: an oligosaccharide, a polysaccharide and an optionally glycosylated polypeptide.
113 . The kit according to any of claims 1 to 111 , wherein the bioactive agent is a polysaccharide.
114 . The kit according to any of claims 1 to 111 , wherein the bioactive agent is an oligosaccharide.
115 . The kit according to any of claims 1 to 111 , wherein the bioactive agent is an optionally glycosylated polypeptide.
116 . The kit according any of claims 1 to 111 , wherein the polysaccharide is a homopolymer.
117 . The kit according any of claims 1 to 111 , wherein the polysaccharide is a heteropolymer.
118 . The kit according any of claims 1 to 117 , wherein the Basidiomycete bioactive agent is an Agaricus bioactive agent is from any of the following: A. blazei, A. blazei Murill, A. bisporus, A. hortensis, A. campestris.
119 . The kit according to any of claims 1 to 117 , wherein the Agaricus bioactive agent is from A. blazei , preferably blazei Murill.
120 . The kit according to any of claims 1 to 117 , wherein the Agaricus bioactive agent is from A. bisporus.
121 . The kit according to any of claims 1 to 117 , wherein the Agaricus bioactive agent is from A. hortensis.
122 . The kit according to any of claims 1 to 117 , wherein the Agaricus bioactive agent is from A. campestris.
123 . The kit according to any of the preceding claims, wherein the Agaricus bioactive agent comprises or consists of an optionally glycosylated peptide.
124 . The kit according to any of claims 1 to 122 , wherein the Agaricus bioactive agent comprises or consists of a polypeptide.
125 . The kit according to any of claims 1 to 122 , wherein the Agaricus bioactive agent comprises or consists of an oligonucleotide.
126 . The kit according to any of claims 1 to 122 , wherein the Agaricus bioactive agent comprises or consists of a polynucleotide.
127 . The kit according to any of claims 1 to 122 , wherein the Agaricus bioactive agent comprises or consists of a lipid.
128 . The kit according to any of claims 1 to 122 , wherein the Agaricus bioactive agent comprises or consists of a fatty acid.
129 . The kit according to any of claims 1 to 122 , wherein the Agaricus bioactive agent comprises or consists of fatty acid esters.
130 . The kit according to any of claims 1 to 122 , wherein the Agaricus bioactive agent comprises or consists of secondary metabolite(s), such as steroids, shikimic acids, alkaloids and benzodiazepins.
131 . The kit according to any of claims 1 to 122 , wherein the Agaricus bioactive agent comprises or consists of at least one steroid.
132 . The kit according to claim 119 , wherein the Agaricus bioactive agent comprises or consists of the (1-4)-alpha D glucan and/or (1-6)-beta-D-glucan described by Fujimiya et al., (“Selective Tumoricial effect of soluble proteoglucan extracted from the basidiomycete, Agaricus blazei Murill, mediated via natural killer cell activation and apoptosis, Cancer Immunol Immunother (1998) 46: 147-159)
133 . The kit according to claim 119 , wherein the Agaricus bioactive agent comprises or consists of the soluble beta-(1-6)-glucans described by Fujimiya et al., (“Peroral effect on tumour progression of soluble beta-(1,6)-glucans prepared by acid treatment from Agaricus blazei . Murr (Agaricaceae, Higher basidiomycetes), International Journal of Medicinal Mushrooms 2, 43-49).
134 . The kit according to any of claims 1 to 117 , wherein the Agaricus bioactive agent comprises or consists of any of the following compounds described by Smith et al., (“Medicinal mushrooms: their therapeutic properties and current medical usage with special emphasis on cancer treatments.”, downloadable from http://sci.cancerresearchuk.org/labs/med_mush/med_mush.html): FI 1 -a-beta (beta-glucan from the fruiting body), FIII2-beta (beta glucan-protein from the fruiting body), FA-1a-beta (hetero-beta glucan from the fruiting body), FA-2b-beta (RNA from the fruiting body), FV-1 (insoluble beta-glucan from the fruiting body), ATOM (glucomannan-protein, isolated from submerged cultured mycelial biomass), AB-FP (mannan protein, isolated from the liquid cultured broth), Beta (1-6)-D-glucan.
135 . The kit according to claim 119 , wherein the Agaricus bioactive agent comprises or consists of the beta-(1-6)-D: -glucan described by Kobayashi et al., (“Suppressing effects of daily oral supplementation of beta-glucan extracted from Agaricus blazei Murill on spontaneous and peritoneal disseminated metastasis in mouse model”, J Cancer Res Clin Oncol. 2005 May 10).
136 . The kit according to claim 119 , wherein the Agaricus bioactive agent comprises or consists of the HM3-G (molecular mass 380 kDa), mainly (1-4)-alpha D glucan with (1-6)-beta branching, described by Fujimiya et al., (“Selective Tumoricial effect of soluble proteoglucan extracted from the basidiomycete, Agaricus blazei Murill, mediated via natural killer cell activation and apoptosis, Cancer Immunol Immunother (1998) 46: 147-159).
137 . The kit according to claim 119 , wherein the Agaricus bioactive agent comprises or consists of Glucomannan with a main chain of beta-1,2-linked D-mannopyranosyl residues and beta-D-glucopyranosyl-3-O-beta-D-glucopyranosyl residues as a side chain described by Mizuno et al. (“Anti-tumor polysaccharide from the mycelium of liquid-cultured Agaricus blazei mill”, Biochem Mol Biol Int. 1999 April; 47(4):707-14).
138 . The kit according to claim 119 , wherein the Agaricus bioactive agent comprises or consists of the polysaccharide fraction prepared using cold or hot NaOH extraction described by Ohno et al., (Antitumor beta glucan from the cultured fruit body of Agaricus blazei . Biol Pharm Bull. 2001 July; 24(7):820-8).
139 . The kit according to claim 119 , wherein the Agaricus bioactive agent comprises or consists of the Glucomannan with a main chain of beta-1,2-linked D-mannopyranosyl residues and beta-D-glucopyranosyl-3-O-beta-D-glucopyranosyl residues as a side chain described by Mizuno et al. (“Anti-tumor polysaccharide from the mycelium of liquid-cultured Agaricus blazei mill”, Biochem Mol Biol Int. 1999 April; 47(4):707-14).
140 . The kit according to claim 119 , wherein the Agaricus bioactive agent comprises or consists of the alpha-1,4-glucan-beta-1,6-glucan complex with an average molecular weight of 20 kDa described by Fujimiya et al., (Tumor-specific cytocidal and immunopotentiating effects of relatively low molecular weight products derived from the basidiomycete, Agaricus blazei Murill. Anticancer Res. 1999 January-February; 19(1A):113-8)
141 . The kit according to claim 119 , wherein the Agaricus bioactive agent comprises or consists of the complex of alpha-1,6- and alpha-1,4-glucan described by Mizuno et al., (Polysaccharides from Agaricus blazei stimulate lymphocyte T-cell subsets in mice. Biosci Biotechnol Biochem. 1998 March; 62(3):434-7).
142 . The kit according to claim 119 , wherein the Agaricus bioactive agent comprises or consists of the ergosterol described by Takaku et al., (Isolation of an antitumor compound from Agaricus blazei Murill and its mechanism of action. J Nutr. 2001 May; 131(5):1409-13).
143 . The kit according to claim 119 , wherein the Agaricus bioactive agent comprises or consists of ATOM (glucomannan-protein, isolated from submerged cultured mycelial biomass) described by Ito et al., “Antitumour effects of a new polysaccharide-protein complex (ATOM) prepared from Agaricus blazei (Iwade strain 101) “Himematsutake” and its mechanisms in tumor-bearing mice”, Anticancer research 17:277-284 (1997).
144 . The kit according to claim 119 , wherein the Agaricus bioactive agent comprises or consists of the FIII-2-b ((1-6)-beta-D-glucan complex) described by Kawagishi et al. (“Formolysis of a potent antitumor (1-6)-beta-D-glucan-protein complex from Agaricus blazei fruiting bodies and antitumor activity of the resulting products. Carbohydr polymers 12:393-403, 1990).
145 . The kit according to claim 119 , wherein the Agaricus bioactive agent comprises or consists of the Isoflavone-beta-D-glucan, produced by culturing Agaricus blazei mycelia in isoflavone-containing liquid medium described in US2005069989.
146 . The kit according to claim 119 , wherein the Agaricus bioactive agent comprises or consists of the Glucomannan having a mannose chain of −1, −2 bonds as its primary chain described in JP 11080206.
147 . The kit according to claim 119 , wherein the Agaricus bioactive agent comprises or consists of the polysaccharide described by Fan et al., “Production of polysaccharide by culinary-medicinal mushroom Agaricus brasiliensis S Wasser et al. LPB 03 (Agaricomycetideae) in submerged fermentation and its antitumor effect”, International Journal of Medicinal Mushrooms 2003), 5(1), 17-23.
148 . The kit according to claim 119 , wherein the Agaricus bioactive agent comprises or consists of the Linoleic acid; and/or 13-hydroxy cis-9, trans-11-octadecadienoic acid (13ZE-LOH) described in “Fruit body of a basidiomycete Agaricus -Blazei”, Yakugaku Zasshi-Journal of the Pharmaceutical Society of Japan 1994.
149 . The kit according to claim 119 , wherein the Agaricus bioactive agent comprises or consists of the Ab-FP described by Liu et al., (“Fractionation of extracellular polysaccharide from Agaricus blazei murill and its antitumor activity”, Shipin Yu Fajiao Gongye (2001), 27(11), 27-29).
150 . The kit according to claim 119 , wherein the Agaricus bioactive agent comprises or consists of the Glucan-protein complex described by Gonzaga et al., (“Isolation and characterisation of polysaccharides from Agaricus blazei Murill”, Carbohydrate polymers 2005, Vol. 60, Iss 1, p 43-49).
151 . The kit according to claim 119 , wherein the Agaricus bioactive agent comprises or consists of the Ap-MP (water-soluble mycelia polysaccharide) described by Liu et al., “Study on antitumor activity of Agaricus blazei”.
152 . The kit according to claim 119 , wherein the Agaricus bioactive agent comprises or consists of the 1SY16 described by Lee et al. (“1SY16 isolated from Agaricus blazei Murill K as a potent multipotential chemopreventative agent”, Cancer Epidemiology Biomarkers and Prevention 2004, Vol 13, Iss 11, p 1861S).
153 . The kit according to claim 119 , wherein the Agaricus bioactive agent comprises or consists of the Sodium pyroglutamate described by Kimura et al. (“Isolation of an anti-angiogenic substance from Agaricus blazei Murill: Its antitumor and antimetastatic actions”, Cancer Science 2004, Vol 95, Iss 9, p758-764)
154 . The kit according to claim 119 , wherein the Agaricus bioactive agent comprises or consists of the Blazeispirane derivatives described by Hirotani et al., (“Blazeispirane and protoblazeispirane derivatives from the cultured mycelia of the fungus Agaricus blazei ”, Phytochemistry 2002, Vol. 61, Iss 5, p 589-595).
155 . The kit according to any of claims 1 - 119 , wherein the Agaricus bioactive agent comprises or consists of any of the basidiolipids BI-1, BI-2, BI-3 or BI-4 as described by Jennemann et al., “Novel glycoinositolphosphosphingolipds, basidiolipds, from Agaricus ”, Eur. J. Biochem. 259, 331-338 (1999).
156 . The kit according to any of the preceding claims, wherein the bioactive agent stimulates the immune system of an animal or a human when administered to said animal or human in a pharmaceutically active amount.
157 . The kit according to claim 156 , wherein the immune stimulating agent is capable of stimulating in an individual in need of such stimulation, the production of one or more of antibodies, such as IgG, IgA, and IgE, T helper cells, interleukins, such as IL-1 and IL-2, interferon, such as IFN-gamma, natural killer cells, and macrophages.
158 . The kit according to any of the preceding claims, wherein the bioactive agent is precipitated by alcohol precipitation.
159 . The kit according to any of the preceding claims, wherein the bioactive agent is precipitated by ultracentrifugation.
160 . The kit according to any of the preceding claims, wherein the bioactive agent is size fractionated prior to precipitation or centrifugation.
161 . The kit according to any of the preceding claims, wherein the bioactive agent is further purified by one or more steps involving washing, desalting, size fractionation, and affinity chromatography, such as ion-exchange chromatography.
162 . The kit according to any of the preceding claims, wherein the bioactive agent is further purified by washing and ion-exchange chromatography.
163 . The kit according to any of the preceding claims, wherein the precipitated immune stimulating agent is further purified by size exclusion chromatography or gel filtration.
164 . The kit according to any of the preceding claims, wherein the bioactive agent is extracellularly located and can be isolated from the liquid growth medium and optionally is also produced intracellularly in said Basidiomycete sp.
165 . The kit according to ally of the preceding claims, wherein the bioactive agent is extracellularly located and immunologically distinct from an intracellularly produced bioactive variant of the agent having the same activity.
166 . The kit according to any of the preceding claims, wherein the liquid growth medium comprises one or more of malt extract, yeast extract, peptone, glucose, sucrose, salts providing phosphate, magnesium and potassium, corn-steep liquor and vitamins, such as thiamine.
167 . The kit according to any of the preceding claims, wherein the Basidiomycete sp. is grown in a liquid growth medium comprising malt extract, yeast extract, peptone, and glucose.
168 . The kit according to any of the preceding claims, wherein the Basidiomycete sp. is grown in a liquid growth medium which is agitated and supplied with an oxygen source.
169 . The kit according to any of the preceding claims, wherein the Basidiomycete sp. is grown at a temperature in the range of from 23° C. to 32° C.
170 . The kit according to any of the preceding claims, wherein Basidiomycete sp. mycelium is removed from the liquid growth medium prior to the isolation of the immune stimulating agent.
171 . The kit according to any of the preceding claims, wherein the fungal mycelium is removed from the initial culture by filtration or centrifugation.
172 . The kit according to any of the preceding claims, wherein said anti-cancer medicament is suitable for administration simultaneously with the administration of the bioactive agent, such as in a co-formulation.
173 . The kit according to any of the preceding claims, wherein said anti-cancer medicament and the bioactive agent are suitable for sequential administration, in any order, such as first the bioactive agent and then the anti-cancer medicament.
174 . The kit according to any of the preceding claims, wherein said medicament and/or agent are suitable for subcutaneous administrationn.
175 . The kit according to any of the preceding claims, wherein said medicament and/or agent are administered nasally.
176 . The kit according to any of the preceding claims, wherein said medicament and/or agent are suitable for administration via the pulmonary route, such as via aerosol administration.
177 . The kit according to any of the preceding claims, wherein said medicament and/or agent are suitable for administration via the parenteral route.
178 . The kit according to any of the preceding claims, wherein said medicament and/or agent are suitable for oral administration.
179 . The kit according to any of the preceding claims, wherein said medicament and/or agent are suitable for topical administration.
180 . The kit according to any of the preceding claims, wherein said medicament and/or agent are co-formulated in a composition.
181 . Use of an anti-cancer medicament and an Basidiomycete sp. bioactive agent for the manufacture of a kit of parts suitable for administration to an individual in need thereof.
182 . The use according to claim 181 , wherein the individual is a mammal, such as a human being.
183 . The use according to any of claims 181 - 182 , wherein said individual is immunocompromised.
184 . The use according to any of claims 181 - 183 , wherein said individual is elderly, such as 60-120 years old, for example 70-120 years old, such as 80-120 years old, for instance 90-120 years old
185 . The use according to any of claims 181 - 183 , wherein said individual is 20-60 years old, such as 30-50 years old.
186 . The use according to any of claims 156 - 183 , wherein said individual is a child, such as from 0-20 years old, for example 0-15 years old, such as 0-10 years old, for example 0-5 years old, such as 0-1 years old, such as a newborn child less than 2 months old.
187 . The use according to any of claims 181 - 186 , wherein said neoplastic disease is benign.
188 . The use according to any of claims 181 - 187 , wherein said neoplastic disease is metastatic.
189 . The use according to any of claims 181 - 188 , wherein said neoplastic disease is stage 3-4 metastatic disease.
190 . The use according to any of claims 81 - 189 , wherein said neoplastic disease is selected from the group consisting of: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Adrenocortical Carcinoma, AIDS-Related Cancers, AIDS-Related Lymphoma, Anal Cancer, Astrocytoma (e.g. Childhood Cerebellar or Childhood Cerebral), Basal Cell Carcinoma, Extrahepatic Bile Duct Cancer, Bladder Cancer, Bone Cancer, Osteosarcoma/Malignant Fibrous Histiocytoma, Brain Stem Glioma, Brain Tumor, Breast Cancer, Male Breast Cancer, Bronchial Adenomas/Carcinoids, Burkitt's Lymphoma, Carcinoid Tumor, Carcinoma of Unknown Primary, Primary Central Nervous System Lymphoma, Cerebral Astrocytoma/Malignant Glioma, Cervical Cancer, Childhood Cancers, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Chronic Myeloproliferative Disorders, Colon Cancer, Cutaneous T-Cell Lymphoma, Endometrial Cancer, Ependymoma (such as Childhood Epdndymoma), Esophageal Cancer, Ewing's Family of Tumors, Extracranial Germ Cell Tumor (such as Childhood Extracranial Germ Cell Tumor), Extragonadal Germ Cell Tumor, Eye Cancer (Intraocular Melanoma or Retinoblastoma), Gallbladder Cancer, Gastric (Stomach) Cancer, Gastrointestinal Carcinoid Tumor, Gestational Trophoblastic Tumor, Glioma, Hairy Cell Leukemia, Head and Neck Cancer, Hepatocellular (Liver) Cancer, Hodgkin's Lymphoma, Hypopharyngeal Cancer, Hypothalamic and Visual Pathway Glioma (such as Childhood Hypothalamic and Visual Pathway Glioma), Intraocular Melanoma, Islet Cell Carcinoma (Endocrine Pancreas), Kaposi's Sarcoma, Kidney (Renal Cell) Cancer, Laryngeal Cancer, Lip and Oral Cavity Cancer, Lung Cancer (Non-Small Cell or Small Cell), Lymphoma (such as AIDS-Related Lymphoma, Burkitt's Lymphoma, Cutaneous T-Cell Lymphoma, Non-Hodgkin's Lymphoma), Macroglobulinemia (such as Waldenstrom's Macroglobulinemia), Malignant Fibrous Histiocytoma of Bone/Osteosarcoma, Medulloblastoma (such as Childhood Medulloblastoma), Melanoma, Merkel Cell Carcinoma, Mesothelioma (such as Adult Malignant Mesothelioma or childhood Mesothelioma), Metastatic Squamous Neck Cancer with Occult Primary, Multiple Endocrine Neoplasia Syndrome (such as occurring in childhood), Multiple Myeloma/Plasma Cell Neoplasm, Mycosis Fungoides, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Myeloma (such as Multiple Myeloma), Chronic myeloproliferative disorders, Nasal Cavity and Paranasal Sinus Cancer, Nasopharyngeal Cancer, Nasopharyngeal Cancer (such as Childhood Nasopharyngeal Cancer), Neuroblastoma, Oropharyngeal Cancer, Osteosarcoma/Malignant Fibrous Histiocytoma of Bone, Ovarian Cancer (such as Childhood Ovarian Cancer), Ovarian Epithelial Cancer, Ovarian Germ Cell Tumor, Ovarian Low Malignant Potential Tumor, Pancreatic Cancer, Pancreatic Cancer, Paranasal Sinus and Nasal Cavity Cancer, Parathyroid Cancer, Penile Cancer, Pheochromocytoma, Pineoblastoma and Supratentorial Primitive Neuroectodermal Tumors, Pituitary Tumor, Pleuropulmonary Blastoma, Prostate Cancer, Renal Pelvis and Ureter Transitional Cell Cancer, Retinoblastoma, Rhabdomyosarcoma (such as Childhood Rhabdomyosarcoma), Salivary Gland Cancer, Adult-onset soft tissue Sarcoma, Soft Tissue Sarcoma (such as Childhood Soft Tissue Sarcoma), uterine Sarcoma, Sezary Syndrome, Skin Cancer (such as non-Melanoma skin cancer), Merkel Cell Skin Carcinoma, Small Intestine Cancer, Supratentorial Primitive Neuroectodermal Tumors (such as occurring in Childhood), Cutaneous T-Cell Lymphoma, Testicular Cancer, Thymoma and Thymic Carcinoma, Thyroid Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Trophoblastic Tumor (such as Gestational Trophoblastic Tumor), Urethral Cancer, Endometrial uterine cancer, Uterine Sarcoma, Vaginal Cancer, Visual Pathway and Hypothalamic Glioma (such as Childhood Visual Pathway and Hypothalamic Glioma), Waldenström's Macroglobulinemia or Wilms' Tumor.
191 . The use according to any of claims 181 - 190 , wherein said Basidiomycete sp. bioactive agent is administered in a dosage from about 0.001 to about 100 mg/kg.
192 . A method for the treatment of a neoplastic disease in an individual, said method comprising the steps of
a. providing the kit of parts according to any of claims 1 to 180 , and b. administering the anti-cancer medicament and a Basidiomycete sp. bioactive agent to said individual.
193 . The method according to claim 192 , comprising any of the aspects specified in claims 1 - 191 .
194 . A method for enhancing the therapeutic effect of an anti-cancer drug, comprising co-administering with said anti-cancer drug a Basidiomycete sp. bioactive agent.
195 . The method according to claim 194 , comprising any of the aspects specified in claims 1 - 191 .Join the waitlist — get patent alerts
Track US2017304415A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.